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increased mortality from tumor in recipients of 7
/
 donor T
cells, suggesting preservation of any graft-versus-tumor activity.
We are currently performing further studies to look at histopa-
thology of GVHD target organs and to analyze T cell inﬁltrates in
GVHD target organs. In summary, 7
/
 donor T cells as
compared to wild type donor T cells cause less GVHD morbidity
and mortality. Our data suggest that strategies that interfere with
the 7 integrin have clinical potential to alleviate or prevent
GVHD while preserving GVT activity.
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DETERMINANTS OF ANTILEUKEMIA EFFECTS OF ALLOGENEIC NATU-
RAL KILLER CELLS
Leung, W.1, Iyengar, R.1, Turner, V.1, Lang, P.2, Bader, P.2, Conn,
P.1, Niethammer, D.2, Handgretinger, R.1 1. St. Jude Children’s
Research Hospital, Memphis, TN; 2. Children’s University Hospital,
Tuebingen, Germany.
In HLA-nonidentical bone marrow transplantation, we sought to
determine the characteristics of donor NK cells, recipient leukemia
cells, and the cytokine environment that predict the antileukemia
effects of allogeneic NK cells. We found that the risk of leukemia
relapse in a prospective cohort of 36 pediatric patients was best
predicted by a model taking into consideration the presence of
inhibitory killer-cell immunoglobulin-like receptors (KIRs) on the
donor’s NK cells and the absence of corresponding KIR ligand in
the recipient’s HLA repertoire (a receptor-ligand model). The risk
of relapse was prognosticated less precisely by the Perugia donor-
recipient KIR ligand-ligand mismatch model or by a natural cyto-
toxicity model. In contrast to the Perugia model, we found that the
new receptor-ligand model was accurate when analysis was applied
to patients with lymphoid malignancy. These ﬁndings corroborate
our observations that the recipient’s KIR repertoire, which was
derived from highly puriﬁed HLA-disparate CD34 cells, always
resumed a donor-speciﬁc pattern within 3 months of transplanta-
tion but did not correlate evidently with either the donor or
recipient ligand repertoire. In an in vitro assay and an in vivo
mouse model, human NK-cell cytotoxicity toward human leuke-
mia cells with 11q23 chromosomal rearrangement increased with
the number of receptor-ligand mismatch pairs or prestimulation
with IL-12 and IL-18. These ﬁndings provide new insights into the
determinants of antileukemia effects of allogeneic NK cells and
therapeutic strategies.
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PROTEINURIA RELATED TO CHRONIC GRAFT-VERSUS-HOST DISEASE
AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Carrasco-Yala´n, A.A.1, Murillo-Vizcarra, S.A.1, Moreno-Larrea, M.1,
Chumpitaz-Anchiraico, G.1, Castillo-Aguirre, J.1, Mendoza, S.1, So-
mocurcio-Peralta, J.2, Liendo-Liendo, C.3, Navarro-Cabrera, J.R.1 1.
BMT Unit-Hematology Department; 2. Anatomy Pathology Depart-
ment; 3. Nephrology Department. Edgardo Rebagliati-Martins National
Hospital. ES-SALUD, Lima, Peru.
Proteinuria related to chronic graft-versus-host disease (GVHD)
is an uncommon manifestation post allogeneic stem cell transplan-
tation (SCT). Several papers have recently addressed this issue. We
report our experience in four allogeneic SCT. Between April-2001
to November-2002, four women received full matched sibling
allografts for aplastic anemia (n  2), RAEB-I (n  1) and CML
(n  1). Median age 28 years (range 20-40). Median time from
diagnosis to transplantation was 7 months (range 6-12). Condi-
tioning regimen for aplastic anemia was: antilymphocyte globu-
lin  cyclophosphamide , for RAEB-I: total body irradiation 
cyclophosphamide, ﬁnally for CML: Busulfan p.o. cyclophosph-
amide. GVHD prophylaxys were given with cyclosporine and
methrothexate . All patient engrafted, neutrophils engraftment at
median of 10 days (range 9-11), non-platelets failure was observed.
Acute GVHD was observed in three cases. Proteinuria during
chronic GVHD exacerbation was developed at a median time of 12
months (range 10-18) post peripheral blood SCT. None of them
developed renal failure neither hypertension. Edema and hy-
poalbuminemia was observed in several degrees. During chronic
GVHD exacerbation, one patient developed lung GVHD, another
polimyositis and two showed positivity to cytomegalovirus (CMV)
antigenemia with extensive GVHD manifestations. Two of them
developed proteinuria at nephrotic range. Renal biopsies were
carried out showing: diffuse proliferative glomerulonephritis,
membranous nephropathy with IgG , C3 and Lambda immune
complex deposit (F/24) and focal intersticial atrophy and ﬁbrosis,
mild membranous nephropathy with C1q immune complex deposit
(F/32). Prednisone based therapy with mycophenolate mofetil (n
3) and cyclosporine (n  1) combined with gancyclovir for CMV
antigenemia, resulted in renal function stabilization and gradual
proteinuria decreases. Currently all of the patients are still alive in
complete remission without transfusion and chronic GHVD im-
provement. Our data suggest that the kidney may be a target organ
in chronic GVHD with immune complex-mediated disease. Fi-
nally we recommend that proteinuria has to be tested under
chronic GVHD exacerbations.
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TACROLIMUS IN COMBINATION WITH STEROIDS FOR THE TREATMENT
OF CHRONIC GVHD
De Jesus, J., Ghosh, S., Hsu, Y., Neuman, J., Cohen, A., Champlin, R.,
Couriel, D. UT MD Anderson Cancer Center, Houston, TX.
Background: Tacrolimus is an effective drug for the treatment of
graft-versus-host disease (GvHD). Recent studies have shown that
tacrolimus may be better than cyclosporine for the prevention of
GvHD. Other studies have shown that it was an effective salvage
therapy for chronic GvHD, even in patients previously treated
with cyclosporine. We report the efﬁcacy of tacrolimus/steroids as
frontline treatment of chronic GvHD. Methods: Retrospective
evaluation of 104 patients who had an allogeneic HSCT between
1/99-12/00 treated with a combination of tacrolimus and steroids
for chronic GvHD. Results: Among the 104 patients (M/F 
74/30), 64 had HLA-matched sibling, 36 matched unrelated and 4
mismatched related transplants. The underlying diseases included:
AML/MDS  33, CML/MPD  25, Lymphoma  28, ALL/
CLL 11, Myeloma 4, others 3. Chronic GvHDwas de novo
in 33 cases, relapsing in 59 and progressive in 12 patients. The
disease was limited in 20 and extensive in 84 patients. In 79% cases
2 organs were involved (skin 84, liver 43, mouth 40, GI
37, eyes  24, lung  13, hematologic  13, musculoskeletal  2,
other  5). GvHD was documented by histology in 56/81 cases
where biopsy examination was performed at the time or following
diagnosis of chronic GvHD. The overall CR/PR rate to tacroli-
mus/steroids was 72% (n  75). Twenty-eight (27%) patients
developed did not respond (NR) or developed progressive disease
(PD). The majority of responses were seen in skin (n  56, 79%)
and oral (n  19, 76%) chronic GvHD. Most failures were seen in
patients with GVHD of the eye (n  5, 50%), GI tract (n  11,
41%) and liver (n  9, 29%). In 49 cases (47%) salvage immuno-
suppression was required after ﬁrst line treatment with tacrolimus/
steroids. The majority of patients (n  34, 69%) responded to
salvage therapy. Fifty patients (48%) in this series died with an
overall cGvHD-related mortality of 34%. Conclusions: Responses
Table. Patients Characteristics
Sex/age
Primary
Disease
Acute-
GVHD
Chronic-
GVHD
Initial
Proteinuria
(mg/24 h)
Proteinuria
Post-SCT
(months)
F/32 Aplastic anemia II Extensive 1248 18
F/40 Aplastic anemia I Extensive 466 15
F/24 RAEB I II Extensive 2294 10
F/20 CML Ph  1CP none Extensive 427 10
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